1-9 of 9
Jerome Goldschmidt
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy

Clinical Trials & Observations
Jonathan W. Friedberg, Rodolfo Bordoni, Dipti Patel-Donnelly, Timothy Larson, Jerome Goldschmidt, Ralph Boccia, Vivian J. M. Cline, Adrija Mamidipalli, Jingmin Liu, Alev Akyol, Christopher A. Yasenchak
Journal: Blood
Blood (2024) 143 (9): 786–795.
https://doi.org/10.1182/blood.2022019536
Published: 2024
Includes: Supplemental data
Journal Articles

Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)

Christopher Yasenchak, Rodolfo Bordoni, Dipti Patel-Donnelly, Timothy Larson, Jerome Goldschmidt, Ralph Boccia, Vivian J. M. Cline, Shweta Jain, Jingmin Liu, Joseph Thaddeus Beck
Journal: Blood
Blood (2023) 142 (Supplement 1): 4435.
https://doi.org/10.1182/blood-2023-190260
Published: 2023
Journal Articles

Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)

Christopher A. Yasenchak, Rodolfo Bordoni, Dipti Patel-Donnelly, Timothy Larson, Jerome Goldschmidt, Ralph V. Boccia, Vivian J.M. Cline, Adrija Mamidipalli, Jingmin Liu, Joseph T. Beck
Journal: Blood
Blood (2022) 140 (Supplement 1): 3685–3686.
https://doi.org/10.1182/blood-2022-156567
Published: 2022
Journal Articles

Efficacy and Safety of Umbralisib, Ublituximab (U2), and U2 Plus Bendamustine in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

John M. Burke, Gustavo Fonseca, Wojciech Jurczak, Jason Melear, Miguel Islas-Ohlmayer, James A Reeves, Parameswaran Venugopal, Tomasz Wróbel, Don Stevens, John M. Pagel, Jerome Goldschmidt, Hari P. Miskin, Peter Sportelli, Owen A. O'Connor, Nilanjan Ghosh
Journal: Blood
Blood (2021) 138 (Supplement 1): 527.
https://doi.org/10.1182/blood-2021-151054
Published: 2021
Journal Articles

Understanding Hematological Adverse Event Management through Health Care Resource Utilization, Costs, and Treatment Patterns of Patients with Extensive-Stage Small Cell Lung Cancer Treated in the Community Oncology Setting

Jerome Goldschmidt, Alisha Monnette, Ping Shi, Divea Venkatasetty, Huan Huang, Marc Chioda
Journal: Blood
Blood (2021) 138 (Supplement 1): 1913.
https://doi.org/10.1182/blood-2021-148057
Published: 2021
Journal Articles

Efficacy and Safety of Ublituximab in Combination with Umbralisib (U2) in Patients with Chronic Lymphocytic Leukemia (CLL) By Treatment Status: A Sub-Analysis of the Phase 3 Unity-CLL Study

Ryan Jacobs, Wojciech Jurczak, Ian W. Flinn, Sebastian Grosicki, Krzysztof Giannopoulos, Tomasz Wróbel, Syed F. Zafar, Jennifer L. Cultrera, Suman Kambhampati, Alexey V. Danilov, John M. Burke, Jerome Goldschmidt, Douglas F. Beach, Scott F. Huntington, Javier Pinilla Ibarz, Jeff P. Sharman, Tanya Siddiqi, Danielle M. Brander, Mazyar Shadman, John M. Pagel, Monika Dlugosz-Danecka, Nilanjan Ghosh, Kathryn S. Kolibaba, Peter Sportelli, Hari P. Miskin, Owen A. O'Connor, Michael S. Weiss, John G. Gribben
Journal: Blood
Blood (2021) 138 (Supplement 1): 3726.
https://doi.org/10.1182/blood-2021-147460
Published: 2021
Journal Articles

Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients

Christopher A. Yasenchak, MD, Rodolfo Bordoni, MD, Dipti Patel-Donnelly, MD, Timothy Larson, MD, Jerome Goldschmidt, MD, Ralph V. Boccia, MD, Vivian J.M. Cline, Mariana Sacchi, MD, Andres Forero-Torres, Robert B. Sims, MD, Jingmin Liu, Jonathan W. Friedberg, MD MSSc
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-136583
Published: 2020
Journal Articles

Umbralisib Plus Ublituximab (U2) Is Superior to Obinutuzumab Plus Chlorambucil (O+Chl) in Patients with Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL): Results from the Phase 3 Unity-CLL Study

John G. Gribben, MD DSc, FRCP, FRCPath, FMedSci, Wojciech Jurczak, MD PhD, Ryan W. Jacobs, MD, Sebastian Grosicki, MD PhD, Krzysztof Giannopoulos, MD PhD, Tomasz Wrobel, MDPhD, Syed F. Zafar, MD, Jennifer L. Cultrera, MD, Suman Kambhampati, MD, Alexey Danilov, MD, John M. Burke, MD, Jerome Goldschmidt, MD, Douglas F. Beach, MD, Scott F. Huntington, MD MPH, Javier Pinilla Ibarz, MD PhD, Jeff P Sharman, MD, Tanya Siddiqi, MD, Danielle M. Brander, MD, John M. Pagel, MDPhD, Kathryn S. Kolibaba, MD, Monika Dlugosz-Danecka, MD PhD, Nilanjan Ghosh, MD PhD, Peter Sportelli, BS, Hari P. Miskin, MSc, Owen A. O'Connor, MD PhD, Michael S. Weiss, Ian W. Flinn, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 37–39.
https://doi.org/10.1182/blood-2020-134783
Published: 2020
Journal Articles

Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older

Clinical Trials & Observations
Andres Forero-Torres, Beata Holkova, Jerome Goldschmidt, Robert Chen, Gregg Olsen, Ralph V. Boccia, Rodolfo E. Bordoni, Jonathan W. Friedberg, Jeff P. Sharman, Maria Corinna Palanca-Wessels, Yinghui Wang, Christopher A. Yasenchak
Journal: Blood
Blood (2015) 126 (26): 2798–2804.
https://doi.org/10.1182/blood-2015-06-644336
Published: 2015
Includes: Supplemental data